Advertise on podcast: LabMind

Change is the new constant—especially in clinical laboratories and healthcare organizations. In this episode of LabMind, Danny Diaz, senior director of Clinical Application Services at Memorial Sloan Kettering Cancer Center, shares why resilience is more than a buzzword—it’s an imperative. As he explores his own career journey, Diaz offers practical strategies for building networks, advancing ideas, advocating for yourself, and driving meaningful transformation. Related Information: When Uncertainty Knocks: How To Regain Control and Reclaim Confidence https://www.linkedin.com/pulse/when-uncertainty-knocks-how-regain-control-reclaim-confidence-diaz-hn6we/?trackingId=XcqMp8lVT6upzDtJUH%2Fnfg%3D%3D

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a genetic condition that can lead to life-threatening hemolysis in both children and adults. Early and accurate diagnosis is critical, but identifying G6PD deficiency in newborns and young children isn’t always straightforward—most reference intervals are based on adult values, which don’t necessarily apply to pediatric patients. In this interview, Dr. Kelly Doyle, an ARUP medical director of Special Chemistry, Endocrinology, and Mass Spectrometry, shares insights from novel methods to establish pediatric-specific reference intervals. Using an innovative indirect approach and a large dataset of patient results, Dr. Doyle explains how these new standards can improve diagnosis and care for children worldwide.  Related Information: Webinar: Development of Pediatric G6PD Reference Intervals Through Integration of Indirect Methods and Molecular Data https://arup.utah.edu/education/doyle-g6pd-2025.php

After seven years and almost 100 episodes of LabMind recorded, Dr. Brian Jackson, former medical director at ARUP Laboratories and faculty with the Spencer Fox Eccles School of Medicine at the University of Utah, has moved into a new clinical laboratory leadership position at the University of Maryland—leaving the podcast mic behind for a clinical challenge he always knew he wanted to take in his career. During Dr. Jackson’s final episode, he shares his thoughts on a variety of topics, including the state of U.S. healthcare and the contributions of pathology, while also reflecting on his time hosting this podcast.    Related Information: • LabMind - An Interview With Dr. Carl Kjeldsberg (Part I): Founding and the Early Shaping of ARUP https://arup.utah.edu/education/podcasts/labmindEp2.php • LabMind - An Interview With Dr. Carl Kjeldsberg (Part II): Scaling ARUP into a Mature Company https://arup.utah.edu/education/podcasts/labmindEp3.php • LabMind - An Interview With Lab Superheroes: Stories of Ingenuity, Creativity, and Grit (Part II) https://arup.utah.edu/education/podcasts/labmindEp50.php • LabMind - An Interview With Rick Panning: How Laboratories Can Reduce the Total Cost of Care https://arup.utah.edu/education/podcasts/labmindEp36.php

In 2016, Dr. Shaiba Ansari-Ali, a rheumatologist with Northwestern Medicine, experienced a near-fatal stroke that was followed by a misdiagnosed case of sepsis. In this interview, she explains how her positivity and tenacity were key to her successful rehabilitation and recovery, and she illustrates how this experience has made her a better physician despite her physical limitations. Related Information: YouTube Series: “Mansplaining Medicine” (https://www.youtube.com/channel/UCkpqin9U2WgT423DqJo2guQwould) Book: “When the Doctor Has a Stroke: (How I recovered, and you can too)” (https://www.amazon.com/dp/B08LNLCLF9/ref=cm_sw_r_cp_ud_dp_G68R6WEVAJEPMFJFY2CP?skipTwisterOG=1)

As laboratory professionals, we’re often focused on our critical role as part of the healthcare team in delivering results to providers. But, do we ever stop and think about the power laboratory data can have in the hands of the patients themselves? In this interview, Cherise Shockley, a diabetes social media advocate, describes her experience being diagnosed with an under-recognized form of diabetes and shares how her continuous glucose monitor (CGM) and laboratory test results have helped her take control of her disease and her life.

Whenever a new infectious disease enters the scene (or reenters, as in the case of measles), developing precise and accurate diagnostic tests as quickly as possible is critical. In this interview, Dr. Ben Bradley, ARUP medical director of the Institute for Research and Innovation in Infectious Disease Genomic Technologies, High Consequence Pathogen Response, Virology, and Molecular Infectious Diseases, describes various challenges in rapidly setting up and maintaining testing capacity for these kinds of diseases and why we need collaboration between academic, clinical, and public health labs. Webinar: Emerging Viral Diseases: A 2025 Update for Laboratorians [https://arup.utah.edu/education/bradley-emergingviral-2025.php]; Measles by Real-Time PCR: A Rapid and Reliable Method for Measles Testing [https://www.youtube.com/watch?v=NZdZDPv-oTw]

In this age of algorithms, how do we ensure clinical care is both science based and personalized? In this interview, Dr. Ryan Metcalf, section chief of Transfusion Medicine at ARUP Laboratories and University of Utah Health and associate professor of Pathology at the University of Utah School of Medicine, shares the story behind the new platelet transfusion guideline from the Association for the Advancement of Blood and Biotherapies (AABB). He describes how the authors addressed patient-specific variation and the inherent uncertainty of scientific evidence.  Related Information:  Platelet Transfusion: 2025 AABB and ICTMG International Clinical Practice Guidelines [https://arup.utah.edu/education/metcalf-platelet-2025.php/]JAMA® Article: Platelet Transfusion: 2025 AABB and ICTMG International Clinical Practice Guidelines [https://jamanetwork.com/journals/jama/fullarticle/2834703]JAMA® Clinical Reviews Podcast: Platelet Transfusion: Best Practice Guidelines [https://edhub.ama-assn.org/jn-learning/audio-player/18977738]

Health equity and personalized medicine share a common goal: tailoring care to the needs of each individual. In this interview, Dr. Octavia Peck Palmer from the University of Pittsburgh Medical Center, immediate past president of ADLM, explains how diversity is foundational to advancing clinical science and improving patient outcomes.

After nearly dying from a mysterious disease during medical school, Dr. David Fajgenbaum dedicated his career to breaking down barriers in biomedical research. Fajgenbaum is now an associate professor of medicine at the University of Pennsylvania and cofounder of Every Cure. In this conversation, we discuss his personal diagnostic journey and the errors and delays he encountered along the way. We also explore why academic medicine needs to go beyond generating disparate pieces of scientific knowledge and instead turn that information into nodes on a network that spans specialty silos to speed the discovery of effective treatments.

Every specimen represents a potential mystery, and laboratory professionals often play the role of detectives. For the 2025 Lab Week episode of LabMind, Amanda Openshaw, a genetic counselor at ARUP, shares examples illustrating the importance of good investigative work in the laboratory to discover accurate diagnoses. 

Why hasn’t there been more progress in developing therapies for Alzheimer’s disease and related forms of dementia? One reason has been the lack of specific laboratory tests that can properly diagnose and characterize these diseases. In this interview, Dr. Qinwen Mao from the University of Utah describes how her research team is helping to bring new blood and cerebrospinal fluid biomarkers into clinical practice to step up the fight against these devastating diseases.  Related Information: Webinar: Innovations in Diagnostics for Alzheimer’s Disease and Related Dementias (aruplab.com/AlzInnovations) 

As laboratory professionals, we may think we have a good understanding of how physicians use our services. But how often do we ask them for practical feedback? In this interview, family physician Dr. Keith Elkins shares his perspectives on what clinical laboratories and pathologists do well, and what opportunities they may be overlooking to better support frontline clinical care. 

Many people in the healthcare profession know that clinical laboratories are under more rigorous regulatory scrutiny than just about any other area of medicine. What they may not know is that the New York State Department of Health (NY DOH) was the pioneer in laboratory regulation, starting long before the implementation of either the FDA Medical Device Amendments or the Clinical Laboratory Improvement Amendments (CLIA) of 1988. In this interview, Beverly Rauch, MS, director of the NY DOH’s Clinical Laboratory Evaluation Program (NY CLEP), describes its process for granting permits, inspecting laboratories, and approving assays, and what the new FDA LDT rule might mean for the program.

In this age of ChatGPT, artificial intelligence (AI), and machine learning, laboratory professionals might think they need to be experts in sophisticated new technology to glean insights from laboratory data. But as ARUP’s medical director of operational informatics Dr. Jenna Rychert points out in this interview, data analysis doesn’t always have to be complicated to provide meaningful value. Related Information: Laboratory-Developed Tests Account for a Small Minority of Tests Ordered in an Academic Hospital System [hyperlinked to: https://pubmed.ncbi.nlm.nih.gov/37265129/ 

Anatomic pathology is on the verge of its biggest technologic shift in over a century. Making a smooth transition will require leadership to pay as much attention to the human impact as to the technology itself. In this discussion, Dr. Suzanne Dintzis from the University of Washington explains why hospital and department leaders will need to partner with front-line laboratory professionals and pathologists who perform the day-to-day work.